Home » Posts tagged 'patent'
Tag Archives: patent
#TEK TekCapital PLC – Patent Filed for ChatGPT Enabled Smart Eyewear
Tekcapital Plc (AIM: TEK, OTCQB: TEKCF), the UK intellectual property investment group notes that Innovative Eyewear, Inc. (“Innovative Eyewear” or the “Company”) (NASDAQ: LUCY; LUCYW), the developer and retailer of smart eyewear under the Lucyd®, Nautica®, and Eddie Bauer® brands, announces today that it has filed a new patent application entitled SYSTEM, APPARATUS, AND METHOD FOR USING A CHATBOT, US Patent Application number 18/189,547.
The software system covered by the patent application focuses on one or more smart devices, which may include smart glasses, that operate with chatbots such as ChatGPT. The inventive application may provide an efficient and effective tool for obtaining a desired response drawn from one or multiple chatbots. The invention accomplishes this by using an innovative technique for choosing from and prioritizing data that may be drawn simultaneously from a number of different chatbots or AI language models. The invention allows for text, audio, and image data to be provided in response to user queries.
“We believe we are the first smart eyewear company to provide (patent-pending), artificial intelligence voice accessibility on Bluetooth-enabled eyewear. With our new Lucyd app, we are continuing to make eyewear more flexible and smarter than ever before,” says Harrison Gross, CEO of Innovative Eyewear.
The Lucyd app provides audible/spoken output of the popular ChatGPT language model, enabling more natural communication between the user and this powerful AI chatbot. The app can be used with any smartphone or hearable device to enable verbal interaction with ChatGPT, including audio glasses made by Innovative Eyewear.
The company will be showcasing its hardware and software at the eMerge tech conference in Miami, FL April 20th-21st and encourages interested parties to attend.
Lucyd Lyte ChatGPT-enabled smart eyewear can be purchased online, in any prescription at Lucyd.co.
Ironically, March 2023 is the 150th anniversary of the introduction of the QWERTY keyboard and production of the Remington typewriter.
On June 23, 1868, a patent was granted to Christopher Sholes, Carlos Glidden, and Samuel W. Soule for a “Type-Writer” which was eventually developed into the Sholes and Glidden typewriter, the first device that allowed an operator to type substantially faster than a person could write by hand. The patent (U.S. patent # 79,265) was sold to Densmore and Yost, who agreed with E. Remington and Sons (then famous as a manufacturer of sewing machines) to commercialize what was known as the Sholes and Glidden Type-Writer. Remington started production of their first typewriter on March 1, 1873, in Ilion, New York. The Type-Writer introduced the QWERTY, designed by Sholes, et al.
|
|
|
Remington No. 1 typewriter (pictured on the right above), made by Remington & Sons, Ilion, NY, 1873-1878. This is the first Sholes & Glidden model typewriter made by Remington & Sons
The mechanical QWERTY keyboard and its digital equivalent can be considered a transitional data entry device, whose importance could be supplanted by more natural and ergonomic interfaces. Voice control on wearables is a key example of an extremely efficient method for interfacing with computing devices, that is faster and more ergonomic than typing. With ChatGPT specifically, the new Lucyd app makes it significantly easier to use, because the typical input into ChatGPT is long-form paragraphs of text which is often too cumbersome to type on a mobile device, requiring the user to be on a desktop computer to use ChatGPT effectively. The Lucyd app makes it fully voice-controlled, and therefore mobile friendly for the first time.
About Innovative Eyewear, Inc.
Innovative Eyewear is a developer and retailer of cutting-edge smart eyewear, under the Lucyd®, Nautica® & Eddie Bauer® brands. True to our mission to Upgrade Your Eyewear®, our Bluetooth audio glasses allow users to stay safely and ergonomically connected to their digital lives, and are offered in hundreds of frame and lens combinations to meet the needs of the optical market. To learn more and explore our continuously evolving collection of smart eyewear, please visit www.lucyd.co.
Tekcapital currently owns 5,189,086 shares (approximately 67%) of Innovative Eyewear, Inc.
For further information, please contact:
|
Tekcapital Plc |
Via Flagstaff |
|
|
Clifford M. Gross, Ph.D. |
||
|
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0) 20 3470 0470 |
|
|
Richard Morrison/Charlie Bouverat (Corporate Finance)/Abigail Wayne / Rob Rees (Corporate Broking)
|
||
|
Flagstaff Strategic and Investor Communications |
|
+44 (0) 20 7129 1474 |
|
Tim Thompson/Andrea Seymour/Fergus Mellon |
|
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
#TEK Tek Capital PLC – Guident Portfolio Company Update
Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF), the UK intellectual property investment group focused on transforming university technologies into valuable products that can improve people’s lives, is pleased to announce that Guident Ltd. (“Guident”) has executed a letter of intent with Auve Tech OÜ (“Auve Tech”) to provide remote monitoring and control (“RMCC”) services for Auve Tech’s autonomous vehicles.
By combining Auve Tech’s advanced Level 4 autonomous vehicles with Guident’s RMCC software, the two companies will bring an enhanced level of safety to self-driving technology. Guident’s patented software provides human-in-the-loop supervision, adding an extra layer of security to the Auve Tech’s new MiCa autonomous shuttle. The Auve Tech next-generation vehicle is capable of autonomous driving in a variety of traffic and weather conditions, making it an ideal solution for safe, reliable, and sustainable transportation in geofenced areas and mixed-traffic environments.
The companies’ plan to launch the Auve Tech MiCa autonomous vehicle combined with Guident’s RMCC software to customers in North America during the second half of 2023.
The Auve Tech autonomous shuttle is aimed at enhancing last-mile transportation offering alternative means of transport in geofenced areas and mixed-traffic environments. Auve Tech has demonstrated its technology in various commercial projects in 12 countries and has proven that its vehicles can provide real autonomous mobility.
“Collaboration is key to driving innovation and progress in the field of autonomous vehicles. We are pleased to have executed a letter of intent (LOI) with Guident to have them provide our autonomous vehicles with their RMCC and monitoring service,” said Johannes Mossov, Chairman of the Management Board of Auve Tech. “This will enable our SAE Level 4 autonomous vehicles to have state-of-the-art, remote monitoring and control upon delivery.”
“The partnership between Guident and Auve Tech represents a step forward in creating safer, smart, and sustainable transportation solutions for communities. We are excited to see the launch of the new MiCa autonomous vehicle with Guident’s RMCC software, which promises to deliver an added layer of safety and reliability in autonomous driving,“ said Harald Braun, Chairman & CEO of Guident Ltd.
|
The Market
According to Triton Market Research “the last mile AV autonomous vehicle delivery market is expected to reach $41.7 billion by 2028 with a CAGR of 19%. Contactless or “touch-free” delivery is in high demand since the COVID-19 pandemic, and Guident believes this increased demand will accelerate the roll-out of land-based delivery drones for pedestrians, food and medicines to improve their availability and reduce the costs of these deliveries.
About Guident
Guident commercializes new technology to enhance the safety, efficiency and utility of autonomous vehicles and ground-based drones using its proprietary IP & software apps for remote monitoring and control. To learn more please visit www.guident.co
About Auve Tech OÜ
Auve Tech specializes on the development and manufacturing of autonomous transportation systems. We offer a full-scope service that entails autonomous vehicles, their integration to various environments and fleet management. To learn more, please visit https://auve.tech/
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
LEI: 213800GOJTOV19FIFZ85
Tekcapital owns 100% of the share capital of Guident Ltd.
For further information, please contact:
|
Tekcapital Plc |
Via Flagstaff |
|
|
Clifford M. Gross, Ph.D. |
||
|
SP Angel Corporate Finance LLP Nominated Adviser and Broker |
+44 (0) 20 3470 0470 |
|
|
Richard Morrison/Charlie Bouverat (Corporate Finance) Abigail Wayne / Rob Rees (Corporate Broking) |
||
|
Flagstaff Strategic and Investor Communications |
|
+44 (0) 20 7129 1474 |
Tim Thompson/Andrea Seymour/Fergus Mellon
#POLB Poolbeg Pharma – US patents granted for POLB 001 and POLB 002
26 May 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections.
POLB 001
The USPTO granted a patent for the majority of Poolbeg’s claims around the use of certain p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment or prevention of severe influenza and the hypercytokinaemia (or “cytokine storm”) it causes through modulation of the immune response (reducing the body’s hyperinflammatory response to the virus). To further strengthen its position, Poolbeg will pursue a continuation patent application to augment the protection offered by this patent family.
Poolbeg holds the worldwide rights to POLB 001 for all uses in humans and as such, is exploring the opportunity to expand its IP around this asset to cover new disease areas which would maximise the value of the asset for partnering purposes.
POLB 002
The USPTO granted a patent for the identification of defective interfering (DI) RNA-based influenza viruses for use against infection by influenza, that provides a drug candidate with both antiviral prophylactic and therapeutic applications. By having a dual mechanism of action POLB 002 (which was identified using this method) directly interferes with influenza virus replication blocking disease progression and also triggers nasal cells into an antiviral state . In this way, POLB 002 could provide pan-viral protection from respiratory virus infections including influenza, respiratory syncytial virus (RSV), SARS-CoV-2 and others.
The Company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“The additional US patent protection of POLB 001 and POLB 002 is an important step in the commercialisation of these novel infectious disease products. Enhancing the IP protection of these assets across key markets such as the US increases the overall value of these products to potential partners, particularly as we move closer to the commencement of our POLB 001 LPS human challenge trial next month with data expected by year end and monetisation to commence thereafter.”
– Ends –
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson
|
+44 (0) 207 220 0500 |
|
Arden Partners PLC (Joint Broker) John Llewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field
|
+44 (0) 20 7457 2020 poolbeg@instinctif.com |
#POLB Poolbeg Pharma – Key POLB 002 European Patent Granted
– Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property (IP) for its asset POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections.
In January this year, Poolbeg secured an exclusive licence for the dual antiviral prophylactic and therapeutic candidate, which is being developed as POLB 002. Data suggests it could provide pan-viral protection from respiratory virus infections including influenza, respiratory syncytial virus (RSV), SARS-CoV-2 and others. As a nasally administered and rapidly effective prophylactic antiviral candidate, it could potentially provide an effective solution for protecting at risk patient populations (e.g. the elderly, COPD patients, and asthmatics).
The European Patent Office has granted this important patent in the POLB 002 patent family, which protects the use of a defective interfering (DI) influenza virus against infection by influenza. POLB 002 works by triggering nasal cells into an antiviral state using DI influenza that resembles the infectious influenza virus but doesn’t have the ability to replicate and therefore can provoke an appropriate immune response but does not cause an infection. The Company will continue working with its patent advisors to broaden and expand this patent family, including the method by which defective interfering antiviral agents can be identified. Discussions with patent authorities in other jurisdictions, including the US, are continuing with further positive announcements expected following a recent ‘Notice of Allowance’ communication from the US patent authorities.
The development of POLB 002 and these patent updates come at a critical time with a global focus on respiratory virus infections and when such viruses are considered a top five global killer, resulting in more than three million annual deaths worldwide. The pandemic potential of influenza continues to be monitored closely by the global health authorities, while the World Health Organization (WHO) and infectious hazard experts have guided that there is statistical certainty that a future influenza pandemic can be expected. The CDC has advised that early action and effective preparedness are absolutely essential to mitigating risk, hence highlighting the importance of developing vaccines, prophylactics and antiviral treatments against viruses; with pan-viral products offering an important solution.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: “The granting of this patent marks an important step in our development and protection of this important respiratory virus disease treatment. Data for POLB 002 shows it is able to both prevent viral infections and rapidly reduce viral loads where infection has occurred, improving disease symptoms and aiding recovery. This makes it an attractive candidate in a market where a significant unmet need for the treatment of most respiratory virus infections still exists.
“Our patent portfolio in Europe, US and elsewhere for POLB 002 are growing as part of our overall strategy to enhance the protection of Poolbeg’s assets and we look forward to updating shareholders on future patent grants.”
– Ends –
Enquiries
| Poolbeg Pharma Plc
Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
| finnCap Ltd (Nominated Adviser & Joint Broker)
Geoff Nash, James Thompson, Charlie Beeson
|
+44 (0) 207 220 0500 |
| Arden Partners PLC (Joint Broker)
John Llewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
| J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
| Instinctif Partners
Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020
poolbeg@instinctif.com |
#TM1 Technology Minerals – Q&A: Building battery recycling capabilities
Technology Minerals is a London-based, LSE-listed company creating a circular economy for battery metals. The company, which is also engaged in extracting raw materials required for lithium-ion (Li-ion) battery cathodes, plans to increase its lead-acid battery recycling capability to 16,000 tonnes per annum by 2022, and 5,000 tonnes per annum for Li-ion batteries in the same time frame.
Robin Brundle, chairman of Technology Minerals plc, outlines TM’s plans to recycle batteries on an industrial scale.
We start full industrial-scale production in early 2022 with two plants, the first, which is currently being installed and will be ready for commissioning in January, is focused on lead-acid battery recycling. The second on lithium-ion battery recycling is now in a manufacture test phase and will be ready for commissioning in February 2022. The sites are both located in the Midlands.
Our recently announced partnership with Slicker Recycling provides a full UK footprint for safe custodianship of collection, of all types of li-ion batteries to our processing plants as we start to build front end inventory during 2022 and grow production. In addition, the wider Slicker group is also very strong in Europe offering a mirror image of the services they offer in the UK. So that could be, at the appropriate time, important for us as we build commercial relationships in Europe.
Can you explain how your recycling process works? How do you get the value out of the so-called ‘black mass’?
The process, for both lead-acid and li-ion, starts through our nationwide collection process and the safe delivery of the batteries to our processing plants in the Midlands.
The li-ion process is industry-leading, and we own the IP on both the process and the plant design. Our process safely deals with all five types of li-ion battery sciences and in any mix or combination at the same time. The plant is modular in design and thus cost effective and each plant can process 5,000 tones per year on a single shift basis. The plant is UK designed, UK manufactured and serviced by a UK company. What sets us apart is that our process does not use pyrolysis or saline solution, and this removes risk to the working environment.
On the lead-acid side, we are industrialising and mechanising a long-established industry that has traditionally been very labour intensive. The efficiencies of the plant combined with our processes really does modernise the sector and will assist in reducing the number of batteries that are either incinerated or worse still sent to landfill.
With regard to black mass, we are working on an end solution for the UK market – it is notable that as it stands – the UK doesn’t currently have the capability to process the black mass back to its constituent parts.
Until the UK has this capability, we have global offtake partners with whom we have already shared testing samples from our process. We already have these offtake partners in place as we build black mass production through 2022.
Are your processes patented and do you intend to license them?
On the li-ion plant, we are currently reviewing our patent applications for both the plant and the process. We are focused on retaining our early to market advantage and will take the necessary steps to do so. The final design and build of the plant have taken nearly two years and is testament to the engineering innovation that we have to hand in such depth in the UK.
UK set for industrial scale battery recycling
On the lead-acid side, we are currently writing a new process to surpass any previous patents that exist. The plant has been sourced from the UK, Europe and Brazil and takes circa eight months from order to completion.
What relationship do you have with Gigafactories?
We have a number of ongoing discussions with the battery OEMs which are at various stages of maturity, and also the tier one auto manufacturers to become their respective partners of choice. Certainly, we aim to build out our plants in line with customer requirements and, where appropriate, creating a bespoke recycling capability on-site which utilises the benefits of our modular processing plant and technology.
You are currently looking at Li-ion batteries from EVs. Do you plan on using other sources (laptops, tablets etc) of battery?
This proprietary process enables us to put all five sciences of lithium-ion batteries through our process, whether that is from portable devices, laptops, e-bikes, through to the heavier end of automotive and energy stations. Each battery type has a slightly different science, and our process allows us to safely recycle any combination through to the output of the ‘black mass’ material, which is rich in a number of the key metals which goes onto the final process of refining back to their respective form.
What markets are you targeting?
Because of the ability of the process to handle all five sciences in lithium-ion batteries we are not restricted as to sector or industry, from the perspective of local authorities looking for safe handling and recycling, through to the automotive OEMs, fleet management and auto dealership networks we have the logistic solution and the re-purposing and then recycling engineering process that really does embrace a circular economy solution for end-of-use and end-of-life batteries.
More broadly, what percentage of your mined products do you expect to introduce into the mix over time?
Our whole strategy is focused on the circular economy, and specifically in the battery sector, and as such we are targeting 100 per cent of all materials being used, be that mined or recycled.
The focus for our recycling operation longer term is on the UK and European markets with a view to grow to 20,000 tonnes of lithium-ion batteries and 60,000 tonnes of lead-acid batteries respectively per annum over the next decade.
The largest market opportunity is in the automotive industry, with 800,000 tonnes of battery per year, equating to ~70 per cent of the battery market in Europe
Lead-acid is the largest battery type with 831,000 tonnes, comprising over 72 per cent of the battery market in Europe.